Johnson's Baby Powder (Ovarian)
OpenFILINGOverview
Subset of the broader Talc MDL 2738 specifically involving ovarian cancer claims from genital use of Johnson's Baby Powder. These claims represent the largest category within the talc litigation.
Causation
Plaintiffs allege regular genital application of Johnson Baby Powder allowed asbestos-contaminated talc particles to migrate through the reproductive tract to the ovaries, causing chronic inflammation and ovarian cancer. Epidemiological studies show a 20-30% increased risk of ovarian cancer with perineal talc use. Internal J&J documents revealed the company knew of asbestos contamination in its talc supply since the 1970s and commissioned studies it later suppressed. Multiple jury verdicts have validated the causation theory, including a USD 4.69B Missouri verdict in 2018.
Defendants
| Entity | Role | Note |
|---|---|---|
| Johnson & Johnson | Manufacturer | Manufactured and marketed Baby Powder for genital hygiene use for decades |
| Johnson & Johnson Consumer Inc. | Subsidiary | Consumer products division — direct seller of Baby Powder |
| Imerys Talc America | Talc Supplier | Supplied talc to J&J — filed Chapter 11 bankruptcy in 2019 |
| LTL Management LLC | Bankruptcy Entity | J&J subsidiary created via Texas Two-Step to manage talc liabilities |
Litigation Timeline
Intelligence Signals
No signals yet. Signals populate automatically when scrapers run.
Key Facts
- Defendants
- Johnson & Johnson
- Injuries
- Ovarian cancer
- Products
- Johnson's Baby Powder
- Status
- active
Geographic Exposure
Eligibility Criteria
- ✓Used Johnson Baby Powder in the genital area regularly
- ✓Diagnosed with ovarian cancer (epithelial ovarian cancer most common)
- ✓Used product for 2+ years before diagnosis
- ✓No genetic predisposition (BRCA mutation) strengthens claim but not required